GlassScriptPhysician profile
Rogeline Jean
NPI 1669011904
$347.41
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $134.68 | 2021 | |
| Astellas Pharma US INC | $75.67 | 2021 | |
| Ucb, INC. | $53.55 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.73 | 2021 | |
| Indivior INC. | $26.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.86 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogeline Jean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.